Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LOEWS CORPL · Entity 3231 | DIRECTOR EMERITUS | June 30, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LOEWS CORP
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,165 |
Reported balance
After 2026-06-30 transaction · row 1
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 102 · Balance 22,165 F1: Represents quarterly grant of common stock in respect of director compensation (prorated for service through the date of his retirement as a director) under the Loews Corporation 2025 Incentive Compensation Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents quarterly grant of common stock in respect of director compensation (prorated for service through the date of his retirement as a director) under the Loews Corporation 2025 Incentive Compensation Plan.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CANTEL MEDICAL CORP
Report date June 02, 2021 · Filed June 02, 2021
Section 16 reporting ended · disclosed 2021-06-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.10 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-06-02 transaction · row 1
1 source rowRow 1 · 2021-06-02 · Disposition to issuer · Disposed 2,865,637 · Balance 0 F1: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. |
| Common Stock, par value $.10 per shareSEC Table I · non-derivative | IndirectBy wife | 0 |
Reported balance
After 2021-06-02 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-06-02 · Disposition to issuer · Disposed 374,112 · Balance 0 F1: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. |
| Common Stock, par value $.10 per shareSEC Table I · non-derivative | IndirectBy custodial accounts for benefit of grandchildren | 0 |
Reported balance
After 2021-06-02 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-06-02 · Disposition to issuer · Disposed 185,928 · Balance 0 F1: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. |
| Common Stock, par value $.10 per shareSEC Table I · non-derivative | IndirectShares held by Dico Group, Inc. | 0 |
Reported balance
After 2021-06-02 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2021-06-02 · Disposition to issuer · Disposed 29,430 · Balance 0 F1: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration"). F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents (i) a portion of shares that, at the effective time of the First Merger (as defined in the Agreement and Plan of Merger, as amended and restated on March 1, 2021 (the "Merger Agreement"), by and among Cantel Medical Corp., a Delaware corporation (the "Company"), STERIS plc, an Irish public limited company ("STERIS"), Solar New US Holding Co, LLC and Crystal Merger Sub 1, LLC) (the "Effective Time"), were converted into the right to receive (i) 0.33787 ordinary shares, par value $0.001 per share, of STERIS (the "Stock Consideration"), and (ii) $16.93 in cash (the "Cash Consideration" and, together with the Stock Consideration, the "Merger Consideration").
F2: Based on the closing price of ordinary shares of STERIS on June 1, 2021, the last trading day before the Effective Time, the value of the Stock Consideration payable per share of common stock, par value $.10 per share, of the Company ("Company Common Stock") was $63.66, and the value of the Merger Consideration payable per share of Company Common Stock pursuant to the Merger Agreement was $80.59 and (ii) a portion of shares that, at the Effective Time, were converted into STERIS equity awards based on an equity award exchange ratio that is intended to preserve the value of the award immediately before and after the conversion.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2016 Filed Dec 15, 2016 21:15 UTC | LOEWS CORP L · Entity 3231 | GrantRestricted Stock Units · Derivative | 3.3 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-089831 · doc1.xml · derivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,531.1 Underlying: Common Stock · 3.3 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: Represents additional RSUs awarded to the Reporting Person on account of dividend equivalent rights associated with previously awarded RSUs (the "Previous RSUs"). F3 · derivative.exercise_date: These RSUs vest, and shares of the Issuer's common stock will be delivered to the Reporting Person, concurrently with Previous RSUs, subject to any election to defer delivery of shares made by the Reporting Person with respect to such Previous RSUs. F3 · derivative.expiration_date: These RSUs vest, and shares of the Issuer's common stock will be delivered to the Reporting Person, concurrently with Previous RSUs, subject to any election to defer delivery of shares made by the Reporting Person with respect to such Previous RSUs. Read SEC document |
| December 09, 2016 Filed Jan 25, 2017 16:50 UTC | CANTEL MEDICAL CORP CMN · Entity 138805 | GiftCommon Stock, par value $.10 per share | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000019446-17-000009 · edgar.xml · nonDerivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 457,288 Read SEC document |
| December 09, 2016 Filed Jan 25, 2017 16:50 UTC | CANTEL MEDICAL CORP CMN · Entity 138805 | GiftCommon Stock, par value $.10 per share | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000019446-17-000009 · edgar.xml · nonDerivative · entry 2 DIKER CHARLES M · CIK 0000905400 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,164,270 Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 21:12 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionStock Appreciation Right · Derivative | 1,500 | $0.00 Strike: $41.85 | $0.00 |
DisclosureSEC source: 0001140361-16-088615 · doc1.xml · derivative · entry 4 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires 2016-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Reporting Person received the Derivative Security pursuant to a stock appreciation right grant at no cost. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 21:12 UTC | LOEWS CORP L · Entity 3231 | SaleCommon Stock | 101 | $45.16 | $4,561.16 |
DisclosureSEC source: 0001140361-16-088615 · doc1.xml · nonDerivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · price: Represents the weighted average price of multiple transactions with a range of prices between $44.87 and $45.19. the Reporting Person, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, undertakes to provide further information regarding the number of securities at each separate price sold. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 21:12 UTC | LOEWS CORP L · Entity 3231 | Disposition to issuerCommon Stock | 1,399 | $44.87 | $62,773.13 |
DisclosureSEC source: 0001140361-16-088615 · doc1.xml · nonDerivative · entry 2 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,101 Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 21:12 UTC | LOEWS CORP L · Entity 3231 | Exercise / conversionCommon Stock | 1,500 | $41.85 | $62,775.00 |
DisclosureSEC source: 0001140361-16-088615 · doc1.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 02, 2016 Filed Jan 25, 2017 16:50 UTC | CANTEL MEDICAL CORP CMN · Entity 138805 | GiftCommon Stock, par value $.10 per share | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000019446-17-000009 · edgar.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By trust for benefit of children Disclosed balance after: 224,271 Read SEC document |
| October 20, 2016 Filed Oct 24, 2016 12:39 UTC | CANTEL MEDICAL CORP CMN · Entity 138805 | SaleCommon Stock, par value $.10 per share | 3,000 | $75.61 | $226,840.80 |
DisclosureSEC source: 0000019446-16-000100 · edgar.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,171,270 F1 · price: The per share prices ranged from $75.60 to $75.69. Upon request by the Commission staff, the issuer or the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 19, 2016 Filed Oct 19, 2016 17:56 UTC Amendment | CANTEL MEDICAL CORP CMN · Entity 138805 | SaleCommon Stock, par value $.10 per share | 1,000 | $76.10 | $76,100.00 |
DisclosureSEC source: 0000019446-16-000099 · edgar.xml · nonDerivative · entry 4 DIKER CHARLES M · CIK 0000905400 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,174,270 Read SEC document |
| October 18, 2016 Filed Oct 19, 2016 17:56 UTC Amendment | CANTEL MEDICAL CORP CMN · Entity 138805 | SaleCommon Stock, par value $.10 per share | 3,000 | $76.58 | $229,749.90 |
DisclosureSEC source: 0000019446-16-000099 · edgar.xml · nonDerivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,175,270 F3 · price: The per share prices ranged from $76.25 to $77.10. Upon request by the Commission staff, the issuer or the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 18, 2016 Filed Oct 19, 2016 17:56 UTC Amendment | CANTEL MEDICAL CORP CMN · Entity 138805 | GrantCommon Stock, par value $.10 per share | 3,295 | $0.00 | $0.00 |
DisclosureSEC source: 0000019446-16-000099 · edgar.xml · nonDerivative · entry 2 DIKER CHARLES M · CIK 0000905400 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,178,270 F2 · date: The Form 4 of the Reporting Person filed on October 12, 2016 reported the acquisition of 3,180 shares of Common Stock on October 10, 2016. Such Form 4 was filed in error as no transaction occured on said date. Rather, the Reporting Person acquired 3,295 shares on October 18, 2016 as reported on this Amendment to the Form 4. Read SEC document |
| October 17, 2016 Filed Oct 19, 2016 17:56 UTC Amendment | CANTEL MEDICAL CORP CMN · Entity 138805 | SaleCommon Stock, par value $.10 per share | 3,000 | $76.14 | $228,433.20 |
DisclosureSEC source: 0000019446-16-000099 · edgar.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,174,975 F1 · price: The per share prices ranged from $75.89 to $76.25. Upon request by the Commission staff, the issuer or the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 10, 2016 Filed Oct 11, 2016 14:58 UTC | CANTEL MEDICAL CORP CMN · Entity 138805 | SaleCommon Stock, par value $.10 per share | 5,036 | $79.15 | $398,609.98 |
DisclosureSEC source: 0000019446-16-000090 · edgar.xml · nonDerivative · entry 3 DIKER CHARLES M · CIK 0000905400 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,177,975 F3 · price: The per share prices ranged from $79.00 to $79.72. Upon request by the Commission staff, the issuer or the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 10, 2016 Filed Oct 12, 2016 17:59 UTC | CANTEL MEDICAL CORP CMN · Entity 138805 | GrantCommon Stock, par value $.10 per share | 3,180 | $0.00 | $0.00 |
DisclosureSEC source: 0000019446-16-000097 · edgar.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,181,155 Read SEC document |
| October 07, 2016 Filed Oct 11, 2016 14:58 UTC | CANTEL MEDICAL CORP CMN · Entity 138805 | SaleCommon Stock, par value $.10 per share | 7,100 | $78.46 | $557,036.18 |
DisclosureSEC source: 0000019446-16-000090 · edgar.xml · nonDerivative · entry 2 DIKER CHARLES M · CIK 0000905400 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,183,011 F2 · price: The per share prices ranged from $78.00 to $79.00. Upon request by the Commission staff, the issuer or the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| October 06, 2016 Filed Oct 11, 2016 14:58 UTC | CANTEL MEDICAL CORP CMN · Entity 138805 | SaleCommon Stock, par value $.10 per share | 2,761 | $78.85 | $217,712.58 |
DisclosureSEC source: 0000019446-16-000090 · edgar.xml · nonDerivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director · Chairman · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,190,111 F1 · price: The per share prices ranged from $78.60 to $79.10. Upon request by the Commission staff, the issuer or the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 13, 2016 Filed Sep 14, 2016 17:12 UTC | LOEWS CORP L · Entity 3231 | GrantRestricted Stock Units · Derivative | 3.8 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-079753 · doc1.xml · derivative · entry 1 DIKER CHARLES M · CIK 0000905400 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,527.8 Underlying: Common Stock · 3.8 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · shares: Represents additional RSUs awarded to the Reporting Person on account of dividend equivalent rights associated with previously awarded RSUs (the "Previous RSUs"). F3 · derivative.exercise_date: These RSUs vest, and shares of the Issuer's common stock will be delivered to the Reporting Person, concurrently with Previous RSUs, subject to any election to defer delivery of shares made by the Reporting Person with respect to such Previous RSUs. F3 · derivative.expiration_date: These RSUs vest, and shares of the Issuer's common stock will be delivered to the Reporting Person, concurrently with Previous RSUs, subject to any election to defer delivery of shares made by the Reporting Person with respect to such Previous RSUs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.